Bone marrow and umbilical cord are both clinically proven MSC sources. Bone marrow has the longer track record, particularly in haematology. Umbilical cord cells offer faster proliferation, lower immune rejection risk, and no invasive harvesting. Neither replaces the other. The right source depends on the condition, patient age, and treatment goal. According to a specialist […]
Physiotherapy manages MS symptoms. Stem cell therapy targets the disease mechanism driving them. For relapsing-remitting MS, MSCs reduce immune-mediated demyelination, support remyelination, and lower relapse frequency outcomes physiotherapy has no pathway to achieve. But physiotherapy remains clinically essential for mobility, spasticity, and functional recovery post-relapse. Used together, they address different layers of the same disease. […]
Stem cell therapy is clinically appropriate for Grade 2 to 3 osteoarthritis where cartilage is damaged but not completely lost. Joint replacement remains the standard for Grade 4 end-stage disease. Many patients, however, are referred to surgery before regenerative options have been properly evaluated. MSCs reduce synovial inflammation, slow cartilage breakdown, and have produced documented […]
Optic nerve atrophy has no conventional cure. Once retinal ganglion cells die and nerve fibres degenerate, standard medicine has nothing to reverse that. Stem cell therapy doesn’t reverse it either, but it does something specific: MSCs protect the RGCs that are still surviving, reduce the inflammation that keeps accelerating damage, and support conditions where some […]
